Skip to main content

Advertisement

Log in

Head tremor secondary to MS resolved with rituximab

  • Case Report
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

We describe the case of a 33-year-old woman who presented with a 2-month history of worsening head tremor. The medical evaluation led to the new diagnosis of MS and the MRI of brain demonstrated prominently active disease. Intravenous rituximab was started according to the HERMES trial, and significant improvement was noted. She has received additional rituximab dosing approximately every 6 months, and at the 2-year follow-up the tremor has not recurred. The resolution of head tremor likely resulted from the complete suppression of MS disease activity, which must have allowed restoration of normal neural circuitry. In agreement with a growing body of evidence that supports early control of MS disease activity to prevent accumulation of fixed disability, this case advocates for aggressive immunological therapy at the onset of tremor in MS patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. http://www.clinicaltrials.gov/ct2/show/NCT00676715.

References

  1. Alusi SH, Worthington J, Glickman S, Bain PG (2001) A study of tremor in multiple sclerosis. Brain 124:720–730

    Article  PubMed  CAS  Google Scholar 

  2. Tranchant C, Bhatia KP, Marsden CD (1995) Movement disorders in multiple sclerosis. Mov Disord 10:418–423

    Article  PubMed  CAS  Google Scholar 

  3. Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688

    Article  PubMed  CAS  Google Scholar 

  4. Weiss N, North RB, Ohara S, Lenz FA (2003) Attenuation of cerebellar tremor with implantation of an intrathecal baclofen pump: the role of gamma-aminobutyric acidergic pathways. Case report. J Neurosurg 99:768–771

    Article  PubMed  Google Scholar 

  5. Sechi GP, Zuddas M, Piredda M et al (1989) Treatment of cerebellar tremors with carbamazepine: a controlled trial with long term follow up. Neurology 39:1113–1115

    PubMed  CAS  Google Scholar 

  6. Koller WC (1984) Pharmacologic trials in the treatment of cerebellar tremor. Arch Neurol 41:280–281

    PubMed  CAS  Google Scholar 

  7. Rice GP, Lesaux J, Vandervoort P, Macewan L, Ebers GC (1997) Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry 62:282–284

    Article  PubMed  CAS  Google Scholar 

  8. Ristori G, Romano S, Visconti A et al (2010) Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 74:839–845

    Article  PubMed  CAS  Google Scholar 

  9. Deuschl G, Raethjen J, Lindemann M, Krack P (2004) The pathophysiology of tremor. Muscle Nerve 24:716–735

    Article  Google Scholar 

  10. Wilms H, Sievers, Deuschl G et al (1999) Animal models of tremor. Mov Disord 14:557–571

    Article  PubMed  CAS  Google Scholar 

  11. Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374:1503–1511

    Article  PubMed  CAS  Google Scholar 

  12. Kappos L, Polman CH, Freedman MS et al (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242–1249

    Article  PubMed  CAS  Google Scholar 

  13. Franciotta D, Salyetti M, Lolli F, Serafini B, Aloisi F (2008) B cells and multiple sclerosis. Lancet Neurol 7:852–858

    Article  PubMed  CAS  Google Scholar 

  14. Centonze D, Furlan R, Gasperini C, Salvetti M, Battistini L (2008) Early relapses after the first dose of natalizumab in active multiple sclerosis patients. Mult Scler 14:1137–1138

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

Dr. Chansakul reports no disclosures. Dr. Moguel-Cobos reports no disclosures. Dr. Bomprezzi has functioned as principal investigator for clinical trials supported by Genzyme Corporation, Novartis, Serono International, Biogen Idec, Genentech Inc, UCB Pharma Inc. He has received honoraria for consulting with Teva Neuroscience, Biogen Idec, Serono International and Genzyme Corporation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Roberto Bomprezzi.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Video Legend. A 33-year-old woman with multiple sclerosis presentting with head tremor. Segment 1. The patient before treatment shows a 2.5-Hz head tremor of the ‘yes-yes’type resolved at full rest. Segment 1. The patient before treatment shows a 2.5-Hz head tremor of the ‘yes-yes’ type resolved at full rest. Supplementary material 1 (WMV 8117 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chansakul, C., Moguel-Cobos, G. & Bomprezzi, R. Head tremor secondary to MS resolved with rituximab. Neurol Sci 32, 1157–1160 (2011). https://doi.org/10.1007/s10072-011-0600-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-011-0600-x

Keywords

Navigation